Shibata Rei, Ouchi Noriyuki, Walsh Kenneth, Murohara Toyoaki
Nagoya University Graduate School of Medicine, Department of Cardiology, 65 Tsurumai, Showa, Nagoya, 466-8550, Japan.
Future Cardiol. 2007 Nov;3(6):647-56. doi: 10.2217/14796678.3.6.647.
In this review, we focus on the role of adiponectin as a cardioprotective agent in several pathological heart conditions. Obesity is closely associated with Type 2 diabetes, hypertension and heart disease. Adiponectin is an adipose tissue-derived hormone whose concentration is downregulated in subjects with obesity-related diseases. Hypoadiponectinemia has been identified as an independent risk factor for Type 2 diabetes, coronary artery disease, acute coronary syndrome and hypertension. More recent experimental findings have shown that adiponectin directly affects signaling in cardiac myocytes and has beneficial effects on several pathological heart conditions, including cardiac hypertrophy and myocardial infarction. The favorable effects of adiponectin are associated with attenuated inflammatory response, decreased myocyte death, decreased hypertrophic response, maintained ischemia-induced angiogenesis and reduced interstitial fibrosis. Therefore, adiponectin could represent a molecular target for treating obesity-linked cardiac diseases.
在本综述中，我们重点关注脂联素作为一种心脏保护剂在几种病理性心脏疾病中的作用。肥胖与2型糖尿病、高血压和心脏病密切相关。脂联素是一种源自脂肪组织的激素，其浓度在患有肥胖相关疾病的个体中下调。低脂联素血症已被确定为2型糖尿病、冠状动脉疾病、急性冠状动脉综合征和高血压的独立危险因素。最近的实验结果表明，脂联素直接影响心肌细胞中的信号传导，并对几种病理性心脏疾病具有有益作用，包括心脏肥大和心肌梗死。脂联素的有利作用与炎症反应减弱、心肌细胞死亡减少、肥大反应降低、缺血诱导的血管生成维持以及间质纤维化减少有关。因此，脂联素可能是治疗肥胖相关心脏疾病的分子靶点。
